Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A systematic review of evidence, across the key pillars of prevention, diagnosis, treatment and prognosis, outlines milestones that need to be met to enable the broad clinical implementation of precision medicine in diabetes care.
The response to neoadjuvant treatment can be used to stratify individuals with muscle-invasive bladder cancer according to their risk of progression, enabling bladder-sparing approaches for some — and heralding a shift from the existing one-size-fits-all approach.
Systematic reviews and meta-analyses are used by clinicians and policymakers to synthesize medical evidence, but they can amplify falsified or poor-quality clinical trial data. In this era of contested evidence, new approaches are needed.
Results from the DiViD Intervention, a phase 2 randomized, placebo-controlled trial, showed that antiviral treatment with pleconaril and ribavirin for 6 months resulted in higher endogenous insulin production in children and adolescents with new-onset type 1 diabetes.
Clinical and population-based cohorts revealed an interaction between the inherited PNPLA3 p.I148M variant and female sex in determining liver disease. Transcriptomic and functional studies showed that the mechanism encompasses ERα-dependent upregulation of PNPLA3 in hepatocytes, highlighting a target for precision medicine therapeutics in cisgender women.
Whole-genome sequencing of Clostridioides difficile from a densely sampled intensive care unit (ICU) population showed that many of these patients harbor toxigenic C. difficile. This carriage did not lead to high levels of cross-transmission but was associated with a greatly increased risk of developing clinically overt C. difficile infection.
In the first-in-human trial of elranatamab, patients with refractory or relapsed multiple myeloma who received the bispecific antibody against BCMA and CD3 experienced no dose-limiting toxicities during dose escalation, and the agent showed promising clinical efficacy.
In a phase 2 trial, the combination of gemcitabine, cisplatin and anti-PD-1 led to a clinical complete response in 43% of patients with muscle-invasive bladder cancer, which facilitated bladder sparing and was associated with long-term bladder-intact metastasis-free survival.
Reactivation of latent SIV with an IAP antagonist, coupled with immunotherapeutic approaches, reduced replication-competent SIV in lymph node CD4+ T cells in rhesus macaques. Further exploration targeting these pathways to reduce the HIV viral reservoir is warranted.
New treatments are essential for methicillin-susceptible Staphylococcusaureus bacteremia, but progress is slow. In this phase III–IV trial, cloxacillin plus fosfomycin failed to show superiority over cloxacillin alone, underscoring the challenges to improving patient outcomes.
In a prospective study, an autism screening app administered using a tablet computer to young children showed high diagnostic accuracy and may facilitate a scalable approach to autism screening.
Nature Medicine explores the latest translation and clinical research news, with results from a clinical trial of Novartis' discontinued gene therapy to restore fetal hemoglobin.
As healthcare systems perform better, their resource footprints have an increasingly negative impact on the environment and health — requiring innovative strategies to break this vicious cycle.
In the LUMINA-1 trial for fibrodysplasia ossificans progressiva, garetosmab, an activin A monoclonal antibody, did not lead to significant changes in heterotopic ossification lesion activity in pre-existing lesions in period 1. Garetosmab prevented the formation of new lesions in both periods 1 and 2.
As the search for new and better treatments for Alzheimer’s disease continues, a phase 1 proof-of-concept study evaluating senolytic therapy breaks new ground.
Grown from stem cells, the models recapitulate the hallmarks of post-implantation human embryos up to day 14, opening new avenues of research into early human development.
Analysis using a combination of molecular and genetic epidemiological approaches reveals an interaction between female sex and the genetic variant PNPLA3 p.I148M that might explain why some women have increased susceptibility to fatty liver disease after onset of menopause.
In patients with Crohn’s disease, CD4+ T cells with cytotoxic TH1 cell-like effector functions reactive against dietary and commensal yeasts are increased in blood and inflamed tissue compared with patients with ulcerative colitis and healthy controls.
We asked leading researchers to share new discoveries about SARS-CoV-2 and COVID-19, from how the virus spreads and the risk of long COVID to the impact of vaccines and masks.
